Diplomat Pharmacy Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
FLINT, Mich., Oct. 16, 2014 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation’s largest independent specialty pharmacy, today announced the closing of its initial public offering of 15,333,333 shares of common stock at an initial public offering price of $13.00 per share, which included 2,000,000 shares sold pursuant to the full exercise of the underwriters’ over-allotment option. Diplomat sold 11,000,000 shares of common stock and certain selling shareholders of Diplomat sold 4,333,333 shares of common stock. The company’s common stock is listed on the New York Stock Exchange under the symbol “DPLO.”
Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC acted as lead book-running managers. Additional book-running managers were J.P. Morgan Securities LLC and Wells Fargo Securities, LLC. William Blair & Company, L.L.C. and Leerink Partners LLC acted as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Copies of the prospectus related to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037, by facsimile at (212) 325-8057, or by email at firstname.lastname@example.org; or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
To learn more, visit diplomat.is.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues – always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Bob East, Westwicke Partners
443-213-0500 | Diplomat@westwicke.com
Jenny Cretu, Diplomat
810.768.9370 | email@example.com
@BusLeadersforMIRT @BusLeadersforMI: Hear from Mike Miller, Director of @Google Tech Services & Phil Hagerman, CEO of @DiplomatRx at 11/9 #MICEOSummit! htt…7 hours ago
@SpecialtyPTimesRT @SpecialtyPTimes: Happy #WorldPharmacistDay to our wonderful followers who make a difference in patient lives every day! How are you cel…11 hours ago
@DiplomatRx@BuntyLUFC We appreciate you reaching out. Would you mind direct messaging us so we can help?5 days ago
@DiplomatRxOur Navigating Patient Engagement webinar is available on demand. Sign up at https://t.co/LN1qWkrCZp to watch the r… https://t.co/RaQGhk3xF75 days ago
@SpecialtyPharmRT @SpecialtyPharm: Specialty Pharmacies Earn High Marks in First NASP Patient Satisfaction @Rx_Specialty Survey #NASP2017 https://t.co/B0k…5 days ago